1. Evaluation of the Antitumor Potential of the Resorcinolic Lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one in Breast Cancer Cells.
- Author
-
Rabacow APM, Meza A, DE Oliveira EJT, DE David N, Vitor N, Antoniolli-Silva ACMB, DE Fátima Cepa Matos M, Perdomo RT, DA Silva Gomes R, DE Lima DP, Beatriz A, and Oliveira RJ
- Subjects
- Breast Neoplasms genetics, Cell Death drug effects, Cell Line, Tumor, Cell Survival drug effects, Female, G2 Phase Cell Cycle Checkpoints drug effects, Gene Expression drug effects, Humans, MCF-7 Cells, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Lipids pharmacology
- Abstract
Background/aim: In recent years, the search for new anticancer experimental agents derived from natural products or synthetic analogues, such as resorcinolic lipids, has received increased attention. The present study aimed to evaluate the antitumor potential, describe the cell death mechanism and the effects of 3-Heptyl-3,4,6-trimethoxy-3Hisobenzofuran-1-one (AMS35AA) in combination with different chemotherapeutic agents in the MCF-7 cell line., Materials and Methods: Analysis of cytotoxic, genotoxic, membrane integrity, cell death and gene expression induced by the compound was performed., Results: The AMS35AA and its association with 5-FU demonstrated reduction of cell viability; increase of cell death; enhancement of genomic damage and accumulation of cells in G
2 /M phase., Conclusion: AMS35AA has potential for breast cancer treatment since it is capable of exerting cytotoxic and cytostatic effects in a breast cell line and also could be an adjuvant in cancer therapy when combined with 5-FU., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF